Varenicline and Risk of Self-Harm: A Nested Case-Control Study.
BACKGROUND
Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates. Post-marketing reports describing suicidal behaviours have raised concerns about the safety of varenicline. However, whether varenicline imparts a higher risk of suicide relative to bupropion remains uncertain.


METHODS
A population-based nested case-control study in Ontario, Canada, from April 1, 2011 to March 31, 2015 was conducted. Subjects were residents of Ontario aged 18 years and older with publicly funded drug coverage receiving either bupropion or varenicline for smoking cessation. We defined cases were those with a hospitalization or emergency department visit for suicide or non-fatal self-harm within 90 days of treatment. For each case, we identified up to fifty controls from the same cohort matched on age, sex, history of self-harm, use of selected psychotropic medications, alcohol abuse and prior admission to a mental health unit. Adjusted odds ratio were used to compare the risk of suicide/self-harm of varenicline to bupropion.


RESULTS
We identified 331 cases and 5,346 matched-controls. Following adjustment for potential confounders, we found that varenicline was not associated with an increased risk of suicide/self-harm relative to bupropion (adjusted odds ratio 1.15; 95% confidence interval 0.71 to 1.87).


CONCLUSIONS
Treatment with varenicline does not appear to significantly increase the risk of suicide or self-harm relative to bupropion.
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.|Institute for Clinical Evaluative Sciences, Toronto, Canada.
Mina
http://orcid.org/0000-0003-1911-6129
M
Tadrous
Institute for Clinical Evaluative Sciences, Toronto, Canada.
Diana
D
Martins
Institute for Clinical Evaluative Sciences, Toronto, Canada.
Zhan
Z
Yao
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.|Institute for Clinical Evaluative Sciences, Toronto, Canada.
Muhammad M
MM
Mamdani
Institute for Clinical Evaluative Sciences, Toronto, Canada.|Sunnybrook Research Institute, Toronto, Canada.
David N
DN
Juurlink
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.|Institute for Clinical Evaluative Sciences, Toronto, Canada.
Tara
T
Gomes
Institute for Clinical Evaluative Sciences, Toronto, Canada.|Department of Family and Community Medicine, St. Michael's Hospital, Toronto, Canada.
Tony
T
Antoniou
JAMA. 2006 Jul 5;296(1):56-63
16820547
BMC Public Health. 2006 Dec 11;6:300
17156479
CMAJ. 2008 Jul 15;179(2):135-44
18625984
BMJ. 2014 Oct 30;349:g6196
25359996
BMJ. 2009 Oct 01;339:b3805
19797344
CMAJ. 2013 Feb 5;185(2):E121-7
23184840
Addiction. 2013 Jul;108(7):1336-43
23445269
Arch Intern Med. 2011 Apr 11;171(7):686-91
21482846
Addiction. 2013 Jan;108(1):203-10
22812921
Eur J Clin Pharmacol. 2011 May;67(5):521-6
21234553
Drug Saf. 2010 Apr 1;33(4):289-301
20297861
Lancet Respir Med. 2015 Oct;3(10):761-8
26355008
Arch Intern Med. 2006 Aug 14-28;166(15):1571-7
16908789
Drug Saf. 2011 Sep 1;34(9):763-72
21830838
PLoS One. 2011;6(11):e27016
22073240
BMJ. 2013 Oct 11;347:f5704
24124105